Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Alleles
Animals
Biomarkers, Tumor
Cell Line
Cellular Reprogramming
/ genetics
Clonal Evolution
Colorectal Neoplasms
/ drug therapy
Computational Biology
DNA Copy Number Variations
Disease Models, Animal
Drug Resistance, Neoplasm
/ genetics
ErbB Receptors
/ antagonists & inhibitors
Gene Expression Profiling
High-Throughput Nucleotide Sequencing
Humans
Mice
Molecular Targeted Therapy
Mutation
Protein Kinase Inhibitors
/ pharmacology
Transcription, Genetic
Exome Sequencing
Xenograft Model Antitumor Assays
Anti-EGFR
PDX
Secondary resistance
Targeted treatment
Transcriptional reprogramming
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
16 07 2021
16 07 2021
Historique:
received:
13
01
2021
accepted:
21
06
2021
entrez:
17
7
2021
pubmed:
18
7
2021
medline:
17
2
2022
Statut:
epublish
Résumé
The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Here we tested in vivo selection of anti-EGFR SR tumors in CRC patient-derived xenograft (PDX) models as a strategy for a molecular dissection of SR mechanisms. We analyzed 21 KRAS, NRAS, BRAF, and PI3K wildtype CRC patient-derived xenograft (PDX) models for their anti-EGFR sensitivity. Furthermore, 31 anti-EGFR SR tumors were generated via chronic in vivo treatment with cetuximab. A multi-omics approach was employed to address molecular primary and secondary resistance mechanisms. Gene set enrichment analyses were used to uncover SR pathways. Targeted therapy of SR PDX models was applied to validate selected SR pathways. In vivo anti-EGFR SR could be established with high efficiency. Chronic anti-EGFR treatment of CRC PDX tumors induced parallel evolution of multiple resistant lesions with independent molecular SR mechanisms. Mutations in driver genes explained SR development in a subgroup of CRC PDX models, only. Transcriptional reprogramming inducing anti-EGFR SR was discovered as a common mechanism in CRC PDX models frequently leading to RAS signaling pathway activation. We identified cAMP and STAT3 signaling activation, as well as paracrine and autocrine signaling via growth factors as novel anti-EGFR secondary resistance mechanisms. Secondary resistant xenograft tumors could successfully be treated by addressing identified transcriptional changes by tailored targeted therapies. Our study demonstrates that SR PDX tumors provide a unique platform to study molecular SR mechanisms and allow testing of multiple treatments for efficient targeting of SR mechanisms, not possible in the patient. Importantly, it suggests that the development of anti-EGFR tolerant cells via transcriptional reprogramming as a cause of anti-EGFR SR in CRC is likely more prevalent than previously anticipated. It emphasizes the need for analyses of SR tumor tissues at a multi-omics level for a comprehensive molecular understanding of anti-EGFR SR in CRC.
Sections du résumé
BACKGROUND
The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Here we tested in vivo selection of anti-EGFR SR tumors in CRC patient-derived xenograft (PDX) models as a strategy for a molecular dissection of SR mechanisms.
METHODS
We analyzed 21 KRAS, NRAS, BRAF, and PI3K wildtype CRC patient-derived xenograft (PDX) models for their anti-EGFR sensitivity. Furthermore, 31 anti-EGFR SR tumors were generated via chronic in vivo treatment with cetuximab. A multi-omics approach was employed to address molecular primary and secondary resistance mechanisms. Gene set enrichment analyses were used to uncover SR pathways. Targeted therapy of SR PDX models was applied to validate selected SR pathways.
RESULTS
In vivo anti-EGFR SR could be established with high efficiency. Chronic anti-EGFR treatment of CRC PDX tumors induced parallel evolution of multiple resistant lesions with independent molecular SR mechanisms. Mutations in driver genes explained SR development in a subgroup of CRC PDX models, only. Transcriptional reprogramming inducing anti-EGFR SR was discovered as a common mechanism in CRC PDX models frequently leading to RAS signaling pathway activation. We identified cAMP and STAT3 signaling activation, as well as paracrine and autocrine signaling via growth factors as novel anti-EGFR secondary resistance mechanisms. Secondary resistant xenograft tumors could successfully be treated by addressing identified transcriptional changes by tailored targeted therapies.
CONCLUSIONS
Our study demonstrates that SR PDX tumors provide a unique platform to study molecular SR mechanisms and allow testing of multiple treatments for efficient targeting of SR mechanisms, not possible in the patient. Importantly, it suggests that the development of anti-EGFR tolerant cells via transcriptional reprogramming as a cause of anti-EGFR SR in CRC is likely more prevalent than previously anticipated. It emphasizes the need for analyses of SR tumor tissues at a multi-omics level for a comprehensive molecular understanding of anti-EGFR SR in CRC.
Identifiants
pubmed: 34271981
doi: 10.1186/s13073-021-00926-7
pii: 10.1186/s13073-021-00926-7
pmc: PMC8283888
doi:
Substances chimiques
Biomarkers, Tumor
0
Protein Kinase Inhibitors
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116Informations de copyright
© 2021. The Author(s).
Références
Cancer Res. 2007 Oct 1;67(19):9364-70
pubmed: 17909045
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
BMC Bioinformatics. 2016 May 10;17:208
pubmed: 27161244
J Clin Oncol. 2009 Oct 20;27(30):5068-74
pubmed: 19738126
Sci Transl Med. 2011 Sep 7;3(99):99ra86
pubmed: 21900593
Cancer Biol Ther. 2013 Dec;14(12):1143-6
pubmed: 24025416
Leukemia. 2012 Jun;26(6):1356-64
pubmed: 22116549
Clin Cancer Res. 2017 Aug 15;23(16):4578-4591
pubmed: 28400427
Nat Commun. 2015 Sep 22;6:8305
pubmed: 26392303
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Clin Cancer Res. 2018 Nov 15;24(22):5602-5609
pubmed: 29898991
Oncotarget. 2016 Apr 5;7(14):18953-64
pubmed: 26980732
Asia Pac J Clin Oncol. 2019 Jun;15(3):128-135
pubmed: 30693649
Cancer Discov. 2011 Nov;1(6):508-23
pubmed: 22586653
PLoS One. 2016 Nov 10;11(11):e0166354
pubmed: 27832189
Nat Methods. 2011 Jun 12;8(8):652-4
pubmed: 21666668
Biochim Biophys Acta. 2013 Jun;1831(6):1146-57
pubmed: 23500889
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Clin Cancer Res. 2017 May 15;23(10):2414-2422
pubmed: 27780856
Hepatology. 2008 Apr;47(4):1298-308
pubmed: 18307269
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Cancer Discov. 2018 Oct;8(10):1270-1285
pubmed: 30166348
Comput Methods Programs Biomed. 2019 Nov;181:104806
pubmed: 30401579
J Biomol Tech. 2018 Jul;29(2):25-38
pubmed: 29805321
Cancer Discov. 2018 Feb;8(2):164-173
pubmed: 29196463
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81
pubmed: 22908275
Nucleic Acids Res. 2013 May 1;41(10):e108
pubmed: 23558742
Gastroenterology. 2009 Jul;137(1):165-75
pubmed: 19328798
Nat Methods. 2006 Jul;3(7):551-9
pubmed: 16791214
Nat Commun. 2018 Sep 19;9(1):3815
pubmed: 30232459
Nat Genet. 2014 Apr;46(4):364-70
pubmed: 24584072
Nat Med. 2015 Jul;21(7):795-801
pubmed: 26030179
Nat Commun. 2016 Feb 19;7:10690
pubmed: 26891683
Nat Med. 2012 Jan 22;18(2):221-3
pubmed: 22270724
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Clin Cancer Res. 2014 Jul 15;20(14):3775-86
pubmed: 24812410
Cancer Biol Ther. 2014 May;15(5):623-32
pubmed: 24556630
Sci Transl Med. 2015 Jan 28;7(272):272ra12
pubmed: 25632036
Mol Carcinog. 2017 Jan;56(1):106-117
pubmed: 26916220
Cancer Cell. 2019 Jul 8;36(1):35-50.e9
pubmed: 31287991
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Oncogene. 2008 Jan 3;27(1):85-97
pubmed: 17599042
J Biol Chem. 2011 May 27;286(21):18515-25
pubmed: 21388956
Nat Commun. 2015 Apr 30;6:7002
pubmed: 25926053
Nat Rev Cancer. 2020 Dec;20(12):743-756
pubmed: 33033407
Sci Transl Med. 2014 Feb 19;6(224):224ra26
pubmed: 24553387
Cancer Cell. 2015 Dec 14;28(6):815-829
pubmed: 26678341
Nat Commun. 2017 May 31;8:15107
pubmed: 28561063
Bioinformatics. 2014 Feb 01;30(3):428-30
pubmed: 24336642
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
J Clin Oncol. 2007 Aug 1;25(22):3230-7
pubmed: 17664471
EMBO Rep. 2014 Nov;15(11):1210-8
pubmed: 25296644
Ann Oncol. 2018 Jan 1;29(1):119-126
pubmed: 28945848
Clin Cancer Res. 2015 May 1;21(9):2157-66
pubmed: 25623215
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Gastroenterology. 2012 May;142(5):1195-1205.e6
pubmed: 22333952
Nature. 2015 Oct 8;526(7572):263-7
pubmed: 26416732
Sci Rep. 2019 Oct 25;9(1):15365
pubmed: 31653970
N Engl J Med. 2009 Apr 2;360(14):1408-17
pubmed: 19339720
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Int J Cancer. 2010 Oct 15;127(8):1941-7
pubmed: 20099280
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
Oncogene. 2018 Mar;37(9):1237-1250
pubmed: 29242606
Genome Med. 2018 Mar 28;10(1):25
pubmed: 29592813
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Nat Med. 2016 Mar;22(3):262-9
pubmed: 26828195
Cancer Discov. 2015 Jun;5(6):598-609
pubmed: 25962717
Genome Res. 2017 Mar;27(3):491-499
pubmed: 28100584
Nat Methods. 2009 Jan;6(1):63-6
pubmed: 19043411
Cell Stem Cell. 2017 Feb 2;20(2):233-246.e7
pubmed: 27989769
Methods Mol Biol. 2013;946:27-38
pubmed: 23179824
Br J Cancer. 2021 Feb;124(3):587-594
pubmed: 33154570
Nat Commun. 2016 Dec 08;7:13665
pubmed: 27929064
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
FEBS J. 2005 Jul;272(14):3491-504
pubmed: 16008550
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Cancer Discov. 2013 Jul;3(7):742-50
pubmed: 23614898
Cancer Res. 2009 May 15;69(10):4388-97
pubmed: 19401450
J Clin Oncol. 2009 Feb 10;27(5):663-71
pubmed: 19114683
Oncogene. 2013 Feb 28;32(9):1121-34
pubmed: 22525277
Int J Clin Oncol. 2020 Aug;25(8):1523-1532
pubmed: 32394048
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Ann Oncol. 2015 Apr;26(4):731-736
pubmed: 25628445
Nature. 2017 Jun 15;546(7658):431-435
pubmed: 28607484
Clin Cancer Res. 2016 Aug 15;22(16):4057-66
pubmed: 26994146
Nucleic Acids Res. 2021 Jan 8;49(D1):D1046-D1057
pubmed: 33221922
Cancer Cell. 2014 Aug 11;26(2):207-21
pubmed: 25065853
Clin Colorectal Cancer. 2013 Mar;12(1):28-36
pubmed: 23083634
Clin Cancer Res. 2015 Sep 15;21(18):4153-64
pubmed: 26019172
Nature. 2017 Aug 10;548(7666):234-238
pubmed: 28783719
Cancer Discov. 2013 Jun;3(6):658-73
pubmed: 23729478